BeStock  
Stocks › Biotechnology › ETRA

ELECTRA THERAPEUTICS INC ETRA

US equityMarket cap rank #3576Biotechnology
$8.11 −$0.83 (-9.28%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.11 0.00%
Open$8.85
Prev close$8.94
Day range$8.07 – $9.65
Volume376.1K
Market cap$509.85M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership64.7%+64.66 pts vs. prior quarter
Institutions holding28+28 vs. prior quarter
Insider trades (recent)8 buys / 0 sellsNet buying
Short interest0.79% of floatDays to cover 1.7 · as of 30 Oct 2026
Short-sale volume share25.4%5-day average of daily volume

Short-sale volume as % of daily volume

0%13%27%41%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$619.5K (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

+$406.8KSuper+$212.7KBig+$269.5KMid+$522.3KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 42.8% of shares outstanding.

Largest holders

  • OrbiMed Advisors LLC11.87%
  • Westlake Village BioPartners10.11%
  • Redmile Group, LLC8.70%
  • EQT Life Sciences6.05%
  • Lsp 7 Cooperatief U.A.6.05%
  • Eqt Fund Management S.à R.L.6.05%
  • New Leaf Venture Partners, LLC5.18%
  • Sanofi3.92%

By investor type

  • VC/PE Fund39.25%
  • Hedge Fund8.93%
  • Public Company7.56%
  • Private Company6.14%
  • Mutual Fund2.52%
  • Individual/Insider1.37%
  • Endowment Fund0.25%

Reported short interest has fallen from 1.15% to 0.79% of float over the last 3 biweekly reports (30 Sep 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +7,449,857 11.9%
Westlake Village BioPartners VC/PE Fund 2026/Q3 +6,347,539 10.1%
Eqt Fund Management S.à R.L. VC/PE Fund 2026/Q3 +3,795,281 6.0%
Sanofi Public Company 2026/Q3 +2,461,948 3.9%
Jefferies Financial Group Inc. Public Company 2026/Q3 +2,244,333 3.6%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +2,055,706 3.3%
Jennison Associates LLC Mutual Fund 2026/Q3 +499,408 0.8%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +417,567 0.7%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +225,156 0.4%
Victory Capital Management Inc. Mutual Fund 2026/Q3 +177,688 0.3%
Ensign Peak Advisors Inc. Endowment Fund 2026/Q3 +158,371 0.3%
Columbia Management Investment Advisers, LLC Mutual Fund 2026/Q3 +127,942 0.2%
Monashee Investment Management, LLC Hedge Fund 2026/Q3 +100,000 0.2%
Y-Intercept (Hong Kong) Limited Mutual Fund 2026/Q3 +21,103 0.0%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +18,205 0.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Nov 2026 OrbiMed Advisors LLC Open Market Acquisition +92,116 $8.45 7,449,857
4 Nov 2026 OrbiMed Advisors LLC Open Market Acquisition +472,571 $7.88 7,357,741
20 Sep 2026 OrbiMed Advisors LLC Private Acquisition +1,333,333 $15.00 6,885,170
20 Sep 2026 OrbiMed Advisors LLC Derivative Exercise and Retained +5,551,837 – 6,885,170
20 Sep 2026 Nancy Stagliano Independent Chairperson Derivative Exercise and Retained +255,635 – 255,635
20 Sep 2026 Graham Parry Chief Scientific Officer Derivative Exercise and Retained +85,504 – 85,504
20 Sep 2026 Quehuong Dong Chief Executive Officer Derivative Exercise and Retained +455,484 – 455,484
20 Sep 2026 Westlake Village BioPartners Initial Statement of Beneficial +0 – 6,347,539
20 Sep 2026 Gary Koe Chief Technology Officer Derivative Exercise and Retained +63,656 – 63,656
17 Sep 2026 Carl Gordon Independent Director Initial Statement of Beneficial +0 – 22,632
17 Sep 2026 Matthew Fust Independent Director Initial Statement of Beneficial +0 – 159,432
17 Sep 2026 David Tucker Senior VP of Finance & Principal Accounting Officer Initial Statement of Beneficial +0 – 187,402
17 Sep 2026 Nancy Stagliano Independent Chairperson Initial Statement of Beneficial +0 – 288,814
17 Sep 2026 Graham Parry Chief Scientific Officer Initial Statement of Beneficial +0 – 187,402
17 Sep 2026 Quehuong Dong Chief Executive Officer Initial Statement of Beneficial +0 – 2,298,219
17 Sep 2026 Kim-Hien Dao Chief Medical Officer Initial Statement of Beneficial +0 – 703,181
17 Sep 2026 Gary Koe Chief Technology Officer Initial Statement of Beneficial +0 – 548,616

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 484,020 0.8% 1.7
15 Oct 2026 409,380 0.7% 1.0
30 Sep 2026 702,266 1.1% 1.0

Discussion

No comments yet — be the first to weigh in on ETRA.

Sign in to join the discussion.

Scroll to Top